{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T16:39:27Z","timestamp":1762015167813,"version":"build-2065373602"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>Gaucher disease (GD) is the most common lysosomal storage disorder, the aim of the current study was to investigate hyperimmunoglobulinemia and abnormalities of serum immunoglobulin G (IgG) subclasses in children with GD and the relation of those findings to the GD phenotype and genotype, duration of enzyme replacement therapy (ERT), and infection frequency. The study included 20 Egyptian children with GD receiving ERT and 20 age-matched and sex-matched healthy children as controls. Serum Ig and serum IgG subclass levels were measured in the children with GD. Serum IgG subclass levels were measured in the control subjects. Hyperimmunoglobulinemia was present in 15 of the 20 (75%) children with GD. In addition, it is found significantly lower IgG2 levels and significantly higher IgG3 levels in the GD group than in the control group (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001 and &lt;0.006, respectively). Patients with 12 infections per year had significantly higher IgG3 levels compared with patients with 6 infections per year (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.022). In conclusion, hyperimmunoglobulinemia and IgG subclass abnormalities occur in children with GD who are on ERT and may be related to recurrent infections.<\/jats:p>","DOI":"10.1097\/mph.0000000000001574","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T16:24:37Z","timestamp":1565022277000},"page":"e416-e420","source":"Crossref","is-referenced-by-count":3,"title":["Hyperimmunoglobulinemia and IgG Subclass Abnormalities in Children With Gaucher Disease"],"prefix":"10.1097","volume":"41","author":[{"given":"Iman","family":"Marzouk","sequence":"first","affiliation":[{"name":"Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Deghady","sequence":"additional","affiliation":[{"name":"Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omneya M.","family":"Omar","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rofaida S.","family":"Ashour","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bjhh.2014.05.005","article-title":"Study of enzyme replacement therapy for Gaucher disease: comparative analysis of clinical and laboratory parameters at diagnosis and after two, five and ten years of treatment","volume":"36","author":"Souza","year":"2014","journal-title":"Rev Bras Hematol Hemoter"},{"key":"R2-20230918","first-page":"79","article-title":"Gaucher\u2019s disease and treatment-an overview","volume":"3","author":"Sireesha","year":"2014","journal-title":"Int J Pharma Res Rev"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"E441","DOI":"10.3390\/ijms18020441","article-title":"A review of Gaucher disease pathophysiology, clinical presentation and treatments","volume":"pii","author":"Stirnemann","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2016.11.006","article-title":"Gaucher disease: progress and ongoing challenges","volume":"120","author":"Mistry","year":"2017","journal-title":"Mol Genet Metab"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0950-3536(97)80032-7","article-title":"Gaucher\u2019s disease: molecular, genetic and enzymological aspects","volume":"10","author":"Grabowski","year":"1997","journal-title":"Baillieres Clin Haematol"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12519-011-0309-1","article-title":"Glucosidase acid beta gene mutations in Egyptian children with Gaucher disease and relation to disease phenotypes","volume":"7","author":"El-Morsy","year":"2011","journal-title":"World J Pediatr"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejmhg.2013.06.002","article-title":"Prenatal genotyping of Gaucher disease in Egypt","volume":"14","author":"Elgawhary","year":"2013","journal-title":"Egypt J Med Hum Genet"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","article-title":"Dose-response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1","volume":"11","author":"Grabowski","year":"2009","journal-title":"Genet Med"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00277-008-0441-8","article-title":"Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature","volume":"87","author":"de Fost","year":"2008","journal-title":"Ann Hematol"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/pbc.24091","article-title":"Hyperimmunoglobulinemia in pediatric Gaucher patients in Southern Brazil","volume":"59","author":"Vairo","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/pbc.22863","article-title":"Immunoglobulin abnormalities and effects of enzyme replacement therapy in children with Gaucher disease","volume":"56","author":"Arikan-Ayyildiz","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MPH.0b013e31806451d3","article-title":"Hyperimmunoglobulinemia in pediatric-onset type 1 Gaucher disease and effects of enzyme replacement therapy","volume":"29","author":"Wine","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0022-1759(94)00331-P","article-title":"Method for quantitation of IgG subclass antibodies in mouse serum by enzyme-linked immunosorbent assay","volume":"181","author":"Gupta","year":"1995","journal-title":"J Immunol Methods"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/(SICI)1096-8628(19981204)80:4<343::AID-AJMG8>3.0.CO;2-W","article-title":"Mutation analysis of Gaucher disease patients from Argentina: high prevalence of the RecNciI mutation","volume":"80","author":"Cormand","year":"1998","journal-title":"Am J Med Genet"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7196\/SAMJ.5439","article-title":"South African guidelines for the management of Gaucher disease, 2011","volume":"102","author":"Bhengu","year":"2012","journal-title":"S Afr Med J"},{"key":"R18-20230918","first-page":"205","article-title":"Cytokines in Gaucher\u2019s disease","volume":"10","author":"Barak","year":"1999","journal-title":"Eur Cytokine Netw"},{"key":"R19-20230918","first-page":"388","article-title":"Gaucher\u2019s disease: a disease with chronic stimulation of the immune system","volume":"106","author":"Shoenfeld","year":"1982","journal-title":"Arch Pathol Lab Med"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood.V104.11.2391.2391","article-title":"High prevalence of B-cell clonality in patients with Gaucher\u2019s disease","volume":"104","author":"Hughes","year":"2004","journal-title":"Blood"},{"key":"R21-20230918","first-page":"479","article-title":"Enzyme replacement therapy decreases hypergammaglobulinemia in Gaucher\u2019s disease","volume":"83","author":"Deibener","year":"1998","journal-title":"Haematologica"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/bcmd.1997.0137","article-title":"Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease","volume":"23","author":"Hollak","year":"1997","journal-title":"Blood Cells Mol Dis"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bcmd.2016.10.016","article-title":"Could enzyme replacement therapy promote immune tolerance in Gaucher disease type 1?","volume":"68","author":"Matta","year":"2018","journal-title":"Blood Cells Mol Diseases"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1056\/NEJM198007243030402","article-title":"Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens","volume":"303","author":"Siber","year":"1980","journal-title":"N Engl J Med"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:07:58Z","timestamp":1695010078000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001574","relation":{},"ISSN":["1077-4114"],"issn-type":[{"type":"print","value":"1077-4114"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}